دورية أكاديمية
Predictors of Shock-Reduction Programming and Its Impact on Implantable Cardioverter-Defibrillator Therapies and Mortality: The CERTITUDE Registry.
| العنوان: | Predictors of Shock-Reduction Programming and Its Impact on Implantable Cardioverter-Defibrillator Therapies and Mortality: The CERTITUDE Registry. |
|---|---|
| المؤلفون: | Beyer SE; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY.; Department of Electrophysiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany., Harrell C; BIOTRONIK Lake Oswego OR., Mullane S; BIOTRONIK Lake Oswego OR., Kutyifa V; Division of Cardiology, Department of Medicine University of Rochester Medical Center Rochester NY., Madhavan M; Department of Cardiovascular Diseases, Mayo Clinic Rochester MN., Piccini JP; Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine Duke University Medical Center Durham NC.; Duke Clinical Research Institute, Duke University Durham NC.; Department of Population Health Sciences Duke University Durham NC., Upadhyay GA; University of Chicago Medicine, Center for Arrhythmia Care, Pritzker School of Medicine, Section of Cardiology Chicago IL., Ip JE; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY., Thomas G; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY., Liu CF; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY., Markowitz SM; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY., Hayes D; BIOTRONIK Lake Oswego OR., Lerman BB; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY., Cheung JW; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York- Presbyterian Hospital New York NY. |
| المصدر: | Journal of the American Heart Association [J Am Heart Assoc] 2024 Jul 16, pp. e034500. Date of Electronic Publication: 2024 Jul 16. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell |
| مستخلص: | Background: Shock-reduction implantable cardioverter-defibrillator programming (SRP) was associated with fewer therapies and improved survival in randomized controlled trials, but real-world studies investigating SRP and associated outcomes are limited. Methods and Results: The BIOTRONIK CERTITUDE registry was linked with the Medicare database. We included all patients with an implantable cardioverter-defibrillator implanted between August 22, 2012 and September 30, 2021 in the United States. SRP was defined as programming to either a therapy rate cutoff ≥188 beats per minute or number of intervals to detection ≥30/40 for treatment. Among 6781 patients (mean 74±9 years; 27% women), 3393 (50%) had SRP. Older age, secondary prevention indication, and device implantation in the southern or western United States were associated with lower use of SRP. The cumulative incidence rate of implantable cardioverter-defibrillator shocks was lower in the SRP group (5.1% shocks/patient year) compared with the non-SRP group (7.2% shocks/patient year) (adjusted hazard ratio [HR], 0.83 [95% CI, 0.73-0.96]; P =0.005). Over a median follow-up of 2.9 years, 739 deaths occurred in the SRP group and 822 deaths occurred in the non-SRP group (adjusted HR, 0.97 [95% CI, 0.88-1.07]; P =0.569). SRP was associated with a lower all-cause mortality among patients without ischemic heart disease compared with patients with ischemic heart disease (adjusted HR, 0.64 [95% CI, 0.48-0.87] versus adjusted HR, 1.02 [95% CI, 0.92-1.14]; P Conclusions: Adoption of SRP is low in real-world clinical practice. Age, clinical variables, and geographic factors are associated with use of SRP. In this study, SRP-associated decrease in mortality was limited to patients without ischemic heart disease. |
| فهرسة مساهمة: | Keywords: implantable cardioverter‐defibrillator programming; mortality; shock‐reduction programming |
| تواريخ الأحداث: | Date Created: 20240716 Latest Revision: 20240716 |
| رمز التحديث: | 20240716 |
| DOI: | 10.1161/JAHA.124.034500 |
| PMID: | 39011955 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2047-9980 |
|---|---|
| DOI: | 10.1161/JAHA.124.034500 |